Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 9k
13 September 2020
Priority question for written answer
to the Commission
Rule 138
Miriam Dalli (S&D)
 Subject: Shortage of medical cannabis in the EU

COVID-19 has affected patients all across the EU, and is expected to impede medical cannabis legislation efforts. The current lack of concrete EU-wide legislation, and proper EU-wide cannabis production and product regulation is becoming a growing problem. For example Malta and Germany have both very recently faced shortages of medical cannabis, causing patients that suffer from chronic pain and medical conditions to face even more disadvantages during a worldwide pandemic. The EU needs a regulated medical cannabis market so patients do not have to resort to the black market to find their medicinal marijuana where products might not be properly regulated.

In light of these recent shortages in the midst of a health crisis:

1. How will the Commission ensure that medical cannabis legislation is not delayed?

2. How will the Commission ensure that patients in every Member State are able to access their medicinal cannabis without delays or shortages?

3. Will the Commission consider speeding up the legislation on medical cannabis and the establishment of an EU-wide regulated medical cannabis market?

Last updated: 16 September 2020Legal notice - Privacy policy